The endocannabinoid system (ECS) has a pivotal role in different cognitive functions such as learning and memory. Recent evidence confirm the involvement of the hippocampal CB1 receptors in the modulation of both memory extinction and reconsolidation processes in different brain areas, but few studies focused on the infralimbic cortex, another important cognitive area. Here, we infused the cannabinoid agonist CP55,940 either into the infralimbic cortex (IL) or the CA1 area of the dorsal hippocampus (HPC) of adult male Wistar rats immediately after a short (3 min) reactivation session, known to labilize a previously consolidated memory trace in order to allow its reconsolidation with some modification. In both structures, the treatment was able to disrupt reconsolidation in a relatively long lasting way, reducing the freezing response. To our notice, this is the first demonstration of ECS involvement in reconsolidation in the Infralimbic Cortex. Despite poorly discriminative between CB1 and CB2 receptors, CP55,940 is a potent agent, and these results suggest that a similar CB1-dependent circuitry is at work both in HPC and in the IL during memory reconsolidation.
Introduction
Converging evidence from several studies does not cease to provide consistent support to a pivotal role for the endocannabinoid system (ECS) in different cognitive processes, with emphasis in learning and memory (e.g., Basavarajappa, Nagre, Xie, & Subbanna, 2014; Quillfeldt & de Oliveira Alvares, 2015, chap. 3; Ratano, Everitt, & Milton, 2014) . CB1 receptors are widely expressed throughout the brain, with significant levels expressed in areas such as the dorsal hippocampus, the basolateral amygdala and the prefrontal cortex, all involved in learning and memory processes (Herkenham et al., 1990; Marsicano & Kuner, 2008) . Endogenous cannabinoids such as anandamide (AEA) or 2-AG, synthesized on demand, act as retrograde modulators of GABA and Glutamate transmission, inhibiting their release inhibit neurotransmitter release by a retrograde action (Katona & Freund, 2012; Kortleven, Fasano, Thibault, Lacaille, & Trudeau, 2011; Szabó et al., 2014) .
A considerable amount of evidence indicates that previously consolidated memories can become labile/unstable after retrieval under certain ''boundary" conditions: a reactivation session consisting of a short-lasting re-exposition to the training context, in the absence of the unconditioned stimulus, allows for the memory trace to become susceptible again to pharmacological and behavioral disruption, undergoing a subsequent re-stabilization process known as reconsolidation (Duvarci & Nader, 2004) . However, when this reactivation session is prolonged beyond a certain critical period, a different process takes place, with the creation of a new trace where the conditioned response has a decreased expression -a process called extinction (Bouton, Westbrook, Corcoran, & Maren, 2006; De Oliveira Alvares, Genro, Diehl, Molina, & Quillfeldt, 2008; Myers & Davis, 2007; Pedreira & Maldonado, 2003) .
Previous findings from our lab show that the administration of the agonist/endogenous CB1 ligand AEA into the hippocampus impaired memory reconsolidation, while the selective CB1 antagonist AM251 enhanced it (De Oliveira Alvares, Genro, Diehl, Molina, et al., 2008) . Both drugs were also effective upon extinction -when infused after a longer, 25 min re-exposure sessionhowever, with remarkable ''opposite" effects: AEA facilitated and AM251 impaired extinction (De Oliveira Alvares, Genro, Diehl, Molina, et al., 2008) .
Effects are not usually that clear when the endogenous ligand anandamide is the drug of choice, since it is difficult to estimate endogenous levels and predict the consequences of the unavoidable fact that they will pool with the exogenously administered quantity (De Oliveira Alvares, . Despite AM251 having a clearcut effect -amnestic upon memory consolidation and facilitatory upon retrieval -AEA was facilitatory upon consolidation and had no effect upon retrieval (De Oliveira Alvares, . This may be due, at least in part, to the fact that anandamide also acts as a TRPV1 endogenous ligand (Ross, 2003) . Indeed, a detailed study from our lab revealed some involvement of the endovanilloid system in memory modulation, but only when strong aversive stimulus (shock) is present: TRPV1 antagonist capsazepine was able to impair memory consolidation, while the agonist capsaicin did not affect any of two different aversive tasks (Genro, de Oliveira Alvares, & Quillfeldt, 2012) .
Recent reports have suggested that endocannabinoid CB1 receptors in the infralimbic cortex (IL), located in the ventromedial region of the prefrontal cortex, may have an important role in the extinction of fear memories: the infusion of the CB1 agonist WIN55212-2 (Lin, Mao, Su, & Gean, 2009) , or the CB1 antagonist cannabidiol (Do Monte, Souza, Bitencourt, Kroon, & Takahashi, 2013) into the IL was shown to facilitate fear memory extinction in rats: despite being a poorly selective indirect CB1 antagonist, cannabidiol is know to potentiate the effects of agonists, and in this work, its effect was blocked by rimonabant, suggesting a CB1-mediated action.
From a therapeutic point of view, extinction has been employed to supress maladaptive memories, but not without its limitations: the progressive decay of emotional response obtained usually do not last and fear response is (spontaneously) recovered over time (Liu et al., 2014; Revillo, Paglini, & Arias, 2014; Schiller et al., 2008) . Since memory reconsolidation seems able to modify the original memory trace and different reports suggest that pharmacological and behavioral inhibition of the reconsolidation process prevent the re-expression of the previously consolidated emotional memories, reconsolidation seems quite promising in clinical terms (Schiller et al., 2010; Yang, Huang, & Hsu, 2011) . The endocannabinoid system has also been proposed as a promising therapeutic target for drugs devised to decrease the impact of maladaptive memories such as those verified in PTSD -post-traumatic stress disorder (De Carvalho, Pamplona, Cruz, & Takahashi, 2014; Ratano et al., 2014) , despite -to this point -clinical trials having been mostly inconclusive (Bucherelli, Baldi, Mariottini, Passani, & Blandina, 2006; Gazarini, Stern, Piornedo, Takahashi, & Bertoglio, 2014; Lee & Flavell, 2014) .
The aim of this study was to verify the effect of the cannabinoid agonist CP55,940, when infused either into the IL cortex, or into the CA1 area of the dorsal HPC after a reactivation session of a contextual fear conditioning.
Materials and methods
One hundred twenty-one Wistar rats (270-320 g) from our breeding colony were used. Animals were housed in plastic cages, four to five per cage, under a 12 h light/dark cycle and at a constant temperature of 24 ± 1°C, with water and food ad libitum. All experiments were conducted in accordance to our federal legislation (Law 11794/2008) and local guidelines for animal care, and the project, approved by the University Ethics Committee (CEUA/ UFRGS Project # 17862).
Rats were deeply anesthetized by an i.p. injection of ketamine/ xylazine (75 and 10 mg/kg, respectively) and bilaterally implanted with 27-gauge guide cannulae aimed 1 mm above the CA1 area of the dorsal hippocampus (AP: À4.0 mm, LL: ±3.0 mm, DV: 1.6 mm) or IL (AP: +3.2 mm, LL: ±0.6 mm, DV: 4.0 mm) from bregma (Paxinos & Watson, 1998) . After a 1 week recovery from surgery, animals were submitted to the behavioral procedures. Following the behavioral experiments, subjects were sacrificed and their brains dissected and preserved in 10% formaldehyde to verify the correct position of the cannula. Only the 106 animals with the correct cannula placement (see Fig. 3 ) were considered in the statistical analysis.
The potent, non-selective cannabinoid receptor agonist CP55,940, was dissolved in phosphate buffered saline (PBS, isotonic) with 8% dimethylsulfoxide to a final concentration of 5 lg/lL (a safe hydrophobic vehicle regularly used in our and other labs -see, e.g., De Oliveira Alvares et al., 2005 Alvares et al., , 2006 ; De Oliveira Alvares, De Oliveira Alvares, Genro, Diehl, Molina, et al., 2008) . At the time of infusion, a 30-gauge infusion needle was fitted into the guide cannulae, with its tip protruding 1.0 mm beyond the guide cannula end, and aimed either to the pyramidal cell layer either of the infralimbic cortex, or -form comparative reasons -the CA1 area of the dorsal hippocampus. In all experiments, a 0.5 lL volume was bilaterally infused in each structure at a slow rate (20 lL/h), and the needle removed after waiting for an additional 30 s.
The conditioning chamber consisted of an (indirectly) illuminated Plexiglas box (20 Â 23 Â 22 cm), with a metallic grid floor of parallel 0.1-cm caliber stainless steel bars spaced 1.0 cm apart. In the training session of the Contextual Fear Conditioning (CFC), rats were left to habituate for 3 min to the conditioning chamber before receiving two 2-s, 0.7-mA footshocks separated by a 30-s interval (the US or unconditioned stimulus) and kept in the conditioning environment for an additional minute before returning to their homecages.
In experiment I subjects were intrahippocampally infused with CP55,940 immediately after training, in three different concentrations (1, 5 and 10 lg/lL) in order to verify the effective concentration able to disrupt memory Consolidation (Fig. 1A) . In experiment II we evaluated if the observed effect was mediated by CB1 receptors verifying if CP55,940 effect could be reversed by a concomitant, subthreshold concentration of the CB antagonist AM251 (Fig. 1B) . Since the effective concentration for intrahippocampally infused AM251 was found to be 5.5 ng/side or 20 lM, dissolved in 0.5 lL volume of vehicle (De Oliveira Alvares, De Oliveira Alvares et al., 2005 , with 2 mM being proven ineffective: that is why we employ 0.2 lM of AM251 to revert the CP55.940 effect, a concentration well bellow the minimum effective value. In experiments III and IV subjects were infused with the effective CP55,940 concentration right after a 180 s context re-exposure (reactivation session) 48 h after training, in order to observe Reconsolidation effects in two successive tests, one 48 h after reactivation, and the other, 7 days later: these Reconsolidation effects were verified for two different brain structures, the CA1 area of the dorsal Hippocampus ( Fig. 2A) , or the Infralimbic cortex (Fig. 2B) . In all tests, animals have their freezing behavior recorded for 4 min in the same conditioning context without the US.
Since data from all experimental groups was proven to be both homoscedastic and normally distributed (Kolmogorov-Smirnov test with Lilliefors' correction, P > 0.05), results were analyzed either with One-way ANOVA followed by a Tukey HSD post hoc test (if needed) -experiments I and II has four independent groups each ( Fig. 1A and B) , or with (2-way) ANOVA for Repeated Measures -experiments III and IV show data for 3 sessions of 2 different groups ( Fig. 2A and B) . Significance level was set at P < 0.05.
Results

CP55,940 infused into the HPC disrupts memory consolidation though a CB1 mediated mechanism
Tree different concentrations of CP55,940 or its vehicle (DMSO 8% in buffered saline) were infused into the CA1 area of the dorsal hippocampus (HPC) immediately after the training session of a Contextual Fear Conditioning. One-Way ANOVA revealed that only the 5 lg/lL concentration has had a significative effect (F(3, 28) = 6.344, P = 0.002, Fig. 1A, N = 8, 8, 8 and 8, respectively) ; post hoc analysis with Tukey's HSD test has shown that this concentration differs significantly both from the Vehicle (P = 0.001) and the CP10 lg/lL (P = 0.033, Tukey post hoc test) groups. In order to confirm that that the poorly selective CP55,940 was indeed acting through CB1 receptors, we infused it concomitantly to a subthreshold (non-effective) concentration of AM251: One way ANOVA revealed significant effect of the drug alone at the 5 lg/lL concentration (F(3, 26) = 7.094, P = 0.001), differing significantly from the vehicle (P = 0.001), and the CP5 + AM0.2 (P = 0.033, Tukey post hoc test) groups, all the other groups being equal (Fig. 1B, N = 8, 8, 8 and 6, respectively) . The area targeted was the pyramidal layer of CA1 region of the dorsal hippocampus, bilaterally infused with drug or its vehicle (see Fig. 3A ). either into (A) the HPC (N = 6 and 8) or (B) the IL cortex (N = 8 and 8), immediately after a 180 s re-exposition to the conditioning context (a reactivation/reconsolidation session) express significantly lower freezing levels observable both in the 3rd (Test 1) and 8th days (Test 2) after reactivation. ANOVA for Repeated Measures showed significant effect for Groups and Sessions and Groups ⁄ Sessions Interaction, P < 0.05 (see text for more details).
revealed a significant effect of Groups, F(1, 12) = 8.819, P = 0.012 and -most important -of Session ⁄ Group Interactions, F(2, 24) = 6.736, P = 0.005, but not of Sessions (F(2, 24) = 2.971, P = 0.070), meaning that these groups do not behave the same way along the successive sessions, with a long lasting amnestic effect of CP55,940 observable both in the first and the second test sessions, remaining persistent up to the 11th day after training (Fig. 2A , N = 6 and 8). Targeted area was the same of the preliminary experiments above (see Fig. 3A ).
Reconsolidation is also disrupted by the post-reactivation infusion of CP55,940 into the IL
CP55,940 or its vehicle were also ninfused into the piramidal layer of the Infralimbic cortex immediately after the 180 s reactivation session: Two-Way ANOVA for Repeated Measures has shown a significant effect of Groups, F(1, 14) = 15.458, P = 0.002, and, also very important, of Session ⁄ Group Interactions, F(2, 28) = 5.691, P = 0.008, however without Sessions effect, (F(2, 28) = 2.843, P = 0.075), meaning that the CP55,940-treated group displays a relatively long lasting amnestic effect, observable from 1 to 8 days after re-exposure/reactivation (Fig. 2B, N = 8 and 8) . The area bilaterally infused was the pyramidal layer of the Infralimbic area of the ventromedial prefrontal cortex (see Fig. 3B ).
Discussion
Our results show a similar involvement, either of the infralimbic cortex or the CA1 region of the dorsal hippocampus, in the processing of memory reconsolidation of an aversive task mediated by CB1 receptors. The potent, yet poorly selective (between CB1 and CB2 receptors) cannabinoid agonist CP55,940 was locally infused in each of these brain areas. The effective concentration of 5 lg/lL, suggested by previous works (Auclair, Otani, Soubrie, & Crepel, 2000 , Bialuk, Dobosz, Potrzebowski, & Winnicka, 2014 , was carefully confirmed here, both for effectiveness (Fig. 1A) and CB1-dependence (Fig. 1B) .
The fact that our agonist CP55,940 did not cause the facilitatory effect we have previously described for anandamide (De Oliveira Alvares, Genro, Diehl, Molina, et al., 2008) came as a surprise. Indeed, the post-reactivation infusion of CP55,940 was more reminiscent of systemic than intracerebral infusion studies -tow different contexts usually characterized by exactly opposite effects (Ameri, 1999; Quillfeldt & de Oliveira Alvares, 2015; Wilson & Nicoll, 2002) . Trying to replicate the facilitation of consolidation observed with AEA, we investigated a broader concentration-response curve than the one displayed in Fig. 1A (data not shown) , to no avail.
This inconsistency can be attributed to two aspects. First, the behavioral tasks used were different: AEA was assayed in the Step-Down Inhibitory Avoidance for consolidation, while CP55,940 was studied in CFC. Second, and more important, the pharmacological differences between both substances -anandamide and CP55,940 in terms of affinity, efficacy, potency and, especially, selectivity. While anandamide is just a partial agonist of CB1 and does not bind to CB2, the most prominent endocannabinoid 2-AG is a full agonist for both receptors (Di Marzo & De Petrocellis, 2012; Sugiura et al., 1997) . CP55,940, that is much more potent than D9-THC (Rinaldi-Carmona et al., 1996) , has a pharmacological profile similar to 2-AG's, with a Ki of 0.6-5.0 and 0.7-2.6 nM for CB1 and CB2, respectively (Thomas, Gilliam, Burch, Roche, & Seltzman, 1998) , and also act as a GPR55 antagonist (Kapur et al., 2009 ). Thus, both agonists, AEA and CP55,940 are poorly selective in different ways. The facilitatory effect we have described of AEA (De Oliveira Alvares, may be explained by the endovanilloid modulation: we found that of TRPV1 antagonist capsazepine blocks consolidation, but agonist capsaicin was ineffective of two aversive tasks (Genro et al., 2012) , which is consistent with the idea of AEA acting through TRPV1.
That was not the case here. Despite the effective reversion of CP55,940 effect by concomitant, subthreshold AM251 supporting a CB1 mediation (Fig. 1B) , the possible involvement of CB2, or even the less well-known GPR55 receptors, may still not be fully discarded as putative explanations for the ''opposite" effect verified. For instance, there is some recent challenge to the classic notion that central neurons do not express CB2 receptors (Brusco, Tagliaferro, Saez, & Onaivi, 2008) : this could open new, interesting avenues of investigation.
Finally, the absence of effect of an agonist in the highest concentration probed normally comes as pharmacological good news, because it confers reliability to the experiment in terms of specificity: the higher the concentration, the more probable it is to bind to other, non-specific targets, where the effect could go from opposite to neutral/compensating. In the case of AEA, also ineffective at the higher concentrations (De Oliveira Alvares, , there is the additional burden represented by the fact that the exogenously infused substance ''pools" with the identical, endogenously released molecules, producing a virtually unknown ''final concentration" (Quillfeldt & de Oliveira Alvares, 2015) . Being an artificial ligand, CP55,940 probably does not behave the same way.
Despite the chosen concentration of 5 lg/lL being based on a post-acquisition paradigm -concerning only consolidation -it was also shown to be effective upon the reconsolidation phase, both when infused into the HPC (Fig. 2A) or the IL cortex (Fig. 2B) , an effect that remained stable for at least 8 more days.
As mentioned above, post-reactivation treatments can affect either extinction or its ''counterpart", reconsolidation, depending on the re-exposure time without the US (Bustos, Maldonado, & Molina, 2009 ): despite involving a disruptive effect analogous to that resulting from a real extinction procedure, we know we are here dealing with reconsolidation, not extinction because exposure time was too short (180 s) and unable to produce a new memory as takes place in na extinction (Bouton, 2004) .
Despite the effect upon consolidation (Fig. 1A and B) differ from previous AEA findings (De Oliveira Alvares, , the reconsolidation disruption was exactly the same effect observed for AEA in the same reconsolidation, in this same behavioral task (De Oliveira Alvares, Genro, Diehl, Molina, et al., 2008) . Thus, at least for the updating of a previously acquired trace, cannabinoid agonists seem to consistently converge to a disruptive action upon reconsolidation. Also, the fact that the very same concentrations of CP55,940 has produced nearly identical effects when infused into such different brain areas, the neocortical IL and the archicortical HPC (compare Fig. 2A and B) , suggests that the local circuitry and/or mechanisms involved may be share some similarities.
The infralimbic region of the prefrontal cortex (IL) has been characterized as a complex relay station acting upon cognitive behavior regulating memory acquisition (Fincham & Anderson, 2006; Gilmartin & Helmstetter, 2010) , consolidation (Laurent & Westbrook, 2009 ) and extinction (Izquierdo, Wellman, & Holmes, 2006; Milad & Quirk, 2002; Thompson et al., 2010) , both through neurotransmitter modulation (Mueller, Porter, & Quirk, 2008) and ample connections with other relevant brain areas (Barker, Taylor, & Chandler, 2014) . Chang and Maren (2010) , e.g., has shown that focal lesions in the IL impaired the retention of extinction in Sprague-Dawley rats. Similarly, there is ample evidence on the involvement of IL in memory extinction from studies applying electrical stimulation during the extinction of FC, usually reducing fear expression and facilitating the consolidation of extinction (Maroun, Kavushansky, Holmes, Wellman, & Motanis, 2012; Milad, Vidal-Gonzalez, & Quirk, 2004; Vidal-Gonzalez, VidalGonzalez, Rauch, & Quirk, 2006) .
It was recently shown that D9-THC alone or co-administered with cannabidiol, was able to persistently disrupt the reconsolidation of a contextual fear memory up to 22 days (Stern et al., 2015) . Similar results has been obtained with WIN55,212, another potent agonist, infused into a different cortical area, the Insular Cortex, during reconsolidation of conditioning taste aversion (Kobilo, Hazvi, & Dudai, 2007) , and into the amygdala, during reconsolidation of fear-potentiated startle (Lin, Mao, & Gean, 2006) . Here, we presented the first demonstration of the involvement of the Infralimbic Cortex in memory reconsolidation through a CB1-mediated mechanism.
Taken together, these findings converge consistently in that, in all these mutually interconnected brain areas, the ECS operates modulating negatively the cognitive process knwon as reconsolidation (see Quillfeldt & de Oliveira Alvares, 2015) , and even an artificial agonist such as CP55,940 was able to disrupt the aversive memory trace when infused during its labile phase. 
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